Advice
Following a resubmission.
Rasagiline (Azilect®) is not recommended within NHS Scotland for the treatment of idiopathic Parkinson’s disease as monotherapy (without levodopa).
Rasagiline provides modest symptomatic improvement for patients with early Parkinson’s disease. The economic case has not been demonstrated.
Download detailed advice55KB (PDF)
Medicine details
- Medicine name:
- rasagiline 1mg tablet monotherapy (Azilect)
- SMC ID:
- 243/06
- Indication:
- Idiopathic Parkinson' s disease as monotherapy (without levodopa)
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 11 December 2006